F6800
Fenoldopam monohydrobromide
≥98%
别名:
6-Chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol monohydrobromide, SKF-82526
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C16H16ClNO3 · HBr
化学文摘社编号:
分子量:
386.67
UNSPSC Code:
12352200
PubChem Substance ID:
EC Number:
266-634-7
MDL number:
InChI key
DSGOSRLTVBPLCU-UHFFFAOYSA-N
InChI
1S/C16H16ClNO3.BrH/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21;/h1-4,7,13,18-21H,5-6,8H2;1H
SMILES string
ClC1=C(O)C(O)=CC2=C1CCNCC2C3=CC=C(O)C=C3.[H]Br
assay
≥98%
form
solid
storage condition
protect from light, under inert gas
color
off-white
solubility
DMSO: >12 mg/mL, H2O: 4.75 mg/mL
storage temp.
2-8°C
Gene Information
human ... ADRA1A(148), ADRA1B(147), ADRA1D(146), DRD1(1812)
Biochem/physiol Actions
Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension. In both an oral and parenteral form, fenoldopam causes peripheral vasodilation by stimulating dopamine-1 adrenergic receptors. Intravenous fenoldopam may provide advantages over sodium nitroprusside because it can induce both a diuresis and natriuresis, is not light sensitive, and is not associated with cyanide toxicity. There is no evidence for rebound hypertension after discontinuation of fenoldopam infusion.
Features and Benefits
This compound was developed by Hospira. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Sens. 1
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
法规信息
新产品
此项目有
T Hussain et al.
The American journal of physiology, 272(3 Pt 2), F339-F346 (1997-03-01)
The dopamine DA1 receptor transduces its signal via adenylyl cyclase and phospholipase C in the renal proximal tubule, which has been suggested to be defective at the level of receptor-G protein coupling in spontaneously hypertensive rats (SHR). We prepared basolateral
M Quevedo et al.
General pharmacology, 32(1), 123-125 (1999-01-15)
1. Fenoldopam mesylate, a benzazepine derivative, is a D1 receptor agonist that lowers blood pressure through vasodilation of renal, mesenteric, coronary and cerebral vascular beds. 2. Experiments were performed in rats, and mean carotid blood pressure and heart rate were
P A de Vries et al.
Journal of cardiovascular pharmacology, 34(2), 191-198 (1999-08-13)
The natriuretic response to a dopamine 1-like receptor agonist is blunted in spontaneously hypertensive rats (SHRs). Whether the renal vasodilator response to D1-like receptor stimulation in SHRs is defective also is unclear. To determine whether the renal hemodynamic response to
Shetal H Padia et al.
Hypertension (Dallas, Tex. : 1979), 59(2), 437-445 (2011-12-29)
Renal dopamine D(1)-like receptors (D(1)Rs) and angiotensin type 2 receptors (AT(2)Rs) are important natriuretic receptors counterbalancing angiotensin type 1 receptor-mediated tubular sodium reabsorption. Here we explore the mechanisms of D(1)R and AT(2)R interactions in natriuresis. In uninephrectomized, sodium-loaded Sprague-Dawley rats
Sapan Talati et al.
Clinical and experimental pharmacology & physiology, 39(6), 506-509 (2012-04-04)
1. Fenoldopam is a dopamine-like receptor agonist that selectively increases renal medullary blood flow. Despite promising pathophysiology, randomized controlled trials have failed to show a benefit with intravenous infusion of fenoldopam in preventing contrast-induced nephropathy (CIN). 2. The aims of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持